• The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection 

      Trøseid, Marius; Mayerhofer, Christiane Caroline; Broch, Kaspar; Arora, Satish; Svardal, Asbjørn M.; Hov, Johannes Espolin Roksund; Andreassen, Arne K.; Gude, Einar; Karason, Kristjan; Dellgren, Gøran; Berge, Rolf Kristian; Gullestad, Lars; Aukrust, Pål; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-06-19)
      <p><i>BACKGROUND - </i>Alterations in the partly microbiota-dependent carnitine–γ-butyrobetaine (γBB)–trimethylamine N-oxide (TMAO) pathway have been linked to the progression of heart failure and atherosclerotic disease. We evaluated if circulating γBB, TMAO, and their common precursors carnitine and trimethyllysine (TML) were dysregulated after heart transplantation and associated with development ...
    • Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression 

      Norum, Hilde Margrethe; Michelsen, Annika; Lekva, Tove; Arora, Satish; Otterdal, Kari; Olsen, Maria Belland; Kong, Xiang Yi; Gude, Einar; Andreassen, Arne K.; Solbu, Dag; Karason, Kristjan; Dellgren, Göran; Gullestad, Lars; Aukrust, Pål; Ueland, Thor (Journal article; Tidsskriftartikkel, 2018-10-12)
      Cardiac allograft vasculopathy (CAV) causes heart failure after heart transplantation (HTx), but its pathogenesis is incompletely understood. Notch signaling, possibly modulated by everolimus (EVR), is essential for processes involved in CAV. We hypothesized that circulating Notch ligands would be dysregulated after HTx. We studied circulating delta‐like Notch ligand 1 (DLL1) and periostin (POSTN) ...
    • Effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo heart transplant recipients - Three-Year results of a Scandinavian randomized trial 

      Arora, Satish; Andreassen, Arne K.; Karason, Kristjan; Gustafsson, Finn; Eiskjær, Hans; Bøtker, Hans Erik; Rådegran, Göran; Gude, Einar; Ioanes, Dan; Solbu, Dag; Dellgren, Göran; Ueland, Thor; Aukrust, Pål; Gullestad, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-09-07)
      <i>Background</i>: Cardiac allograft vasculopathy (CAV) limits survival after heart transplantation, and the effect of different immunosuppressive regimens on CAV is not fully understood. The randomized SCHEDULE trial (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) evaluated whether initiation of the proliferation signal inhibitor ...